Amgen Market Cap: 59.04B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AMGN Market Cap Rankings
| Overall | 98th percentile | 88 of 4673 |
| Sector | 98th percentile | 10 of 530 in Healthcare |
| Industry | 99th percentile | 1 of 164 in Biotechnology |
AMGN Market Cap Range, Past 5 Years
| Minimum | 43.51B | Jun 2002 |
| Maximum | 98.30B | Sep 2005 |
| Average | 73.00B |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these AMGN related companies
AMGN News
FDA panel of cancer experts voted against use for $AMGN Xgeva in prostate cancer. http://stks.co/2K65
about 3 days ago by abubnic
about 3 days ago by abubnic
$DNDN Analyst Says FDA Panel Rejection on $AMGN XGEVA Would Not Positively Affect DNDN's PROVENGE, as they Are Not Mutually Exclusive
about 4 days ago by Benzinga
about 4 days ago by Benzinga
@GArgondizza Yea need the bio's to come back. currently in 4 of this site's favs $VVUS $ACHN $AMGN $IDIX....bought $SODA earlier bc of $GMCR
about 4 days ago by collegefb81
about 4 days ago by collegefb81
With $AMGN failure of #Xgeva, does this mean they will make a play for $DNDN? Time will tell.
about 4 days ago by skrochta
about 4 days ago by skrochta
Amgen $AMGN fails to win panel backing for expanded Xgeva cancer use; vote was 12-1 against
about 4 days ago by Street_Insider
about 4 days ago by Street_Insider
Amgen (AMGN) fails to win panel backing for expanded Xgeva cancer use -Bloomberg
Feb 08, 12:09PM Street Insider
Feb 08, 12:09PM Street Insider
$DNDN looking weak after breakout on Monday.....sellers exiting before $AMGN FDA news
about 4 days ago by skrochta
about 4 days ago by skrochta
Canaccord Genuity raises $DNDN price target to $18 on low likelihood of $AMGN competitive drug approval. http://stks.co/2IIm
about 5 days ago by abubnic
about 5 days ago by abubnic
In 1990 we traded $AMGN at EF Hutton / Lehman and well nobody knew who they were... http://stks.co/2EjE
about 9 days ago by EXPstocktrader
about 9 days ago by EXPstocktrader
$AMGN http://stks.co/2D0f Been moving strongly and breaking out again yesterday; watch over yest high
about 10 days ago by fornix
about 10 days ago by fornix
Biotechs are red hot right now just like around this time last year $ibb, $biib, $amgn $vrtx ect. ect.
about 11 days ago by doomdog144
about 11 days ago by doomdog144
$AMGN http://stks.co/2C9S based on IBB, $BIIB strength, $AMGN looks ready here
about 11 days ago by dangerrangers
about 11 days ago by dangerrangers
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AMGN | 67.36 | 0.52 | 0.78% | 59.04B |
| ENTR | 7.09 | -0.17 | -2.27% | 615.77M |
| ANEN | 18.30 | -0.15 | -0.81% | 275.23M |
| FREE | 0.64 | -0.06 | -8.59% | 4.15M |
| T | 29.84 | -0.15 | -0.50% | 176.83B |
| CV | 35.17 | 0.06 | 0.17% | 471.98M |
| AA | 10.29 | -0.35 | -3.29% | 10.95B |
| COST | 84.20 | -0.33 | -0.39% | 36.49B |
| EQIX | 128.48 | -2.47 | -1.89% | 6.04B |
| RVBD | 27.67 | -0.06 | -0.22% | 4.30B |
